Get started
Author

Paul Tomondy

Observed names: P. Tomondy, Paul A. Tomondy
OpenAlex ID: A5001984029
Continued Treatment with Dupilumab is Associated with Improved Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Not Achieving Optimal Responses with Short-Term Treatment
2021 · April Armstrong, Andrew Blauvelt, et al. · Dermatology and Therapy · 15
PDF
52742 Real-world patient/clinician-reported outcomes of tirbanibulin for actinic keratosis: indirect comparison between KLIR and PROAK studies
2024 · Todd Schlesinger, Ismail Kasujee, et al. · Journal of the American Academy of Dermatology · 1
43757 Improvement in pigmentation changes by Fitzpatrick skin type in actinic keratosis patients treated with tirbanibulin ointment 1%: pooled data from two Phase III studies
2023 · Andrew Blauvelt, Edward Lain, et al. · Journal of the American Academy of Dermatology · 1
PDF
382 Dupilumab treatment provides continued improvements in signs and symptoms through week 100 in patients with moderate-to-severe atopic dermatitis who did not achieve ≥75% reduction in eczema area and severity index at week 16
2020 · A.W. Armstrong, A. Blauvelt, et al. · Journal of Investigative Dermatology · 1
PDF
Fluoroquinolone-Use EvaluaHon for Acute Cystitis
1996 · Don Whipps, Linda Zebrowski, et al. · Journal of Managed Care Pharmacy · 1
PDF
76791 Efficacy of sarecycline in the treatment of moderate-to-severe facial acne vulgaris (AV): Combined results from three phase 3 studies
2026 · James Del Rosso, Linda Stein Gold, et al. · Journal of the American Academy of Dermatology
76696 Achieving complete clearance (CC) in actinic keratosis (AK) after treatment with tirbanibulin 1% with mild to moderate local skin reactions (LSRs): a pooled post-hoc analysis of three Phase III studies
2026 · Edward (Ted) Lain, Naiem T. Issa, et al. · Journal of the American Academy of Dermatology
76748 Efficacy of Tirbanibulin 1% Beyond Complete Clearance (CC): Percent Reduction of Actinic Keratosis (AK) Lesions as a Clinically Meaningful Endpoint
2026 · Neal Bhatia, Julia Welzel, et al. · Journal of the American Academy of Dermatology
Use of Oral Sarecycline as Monotherapy and in Combination With Topical Treatments in Patients With Acne: A Post-Hoc Analysis of Results From the Patient Reported Outcomes for Sarecycline Effectiveness and Safety (PROSES), a Single-Arm Prospective Cohort Study
2025 · Hilary Baldwin, Elizabeth Swanson, et al. · SKIN The Journal of Cutaneous Medicine
PDF
64551 Patient outcomes and satisfaction with tirbanibulin for the treatment of actinic keratosis (AK): Results from post-registration studies
2025 · Todd Schlesinger, Vishal Patel, et al. · Journal of the American Academy of Dermatology
64582 Relating patient-reported treatment satisfaction and clinical outcomes in post-registration studies of tirbanibulin for actinic keratosis (AK)
2025 · Leon Kircik, Todd Schlesinger, et al. · Journal of the American Academy of Dermatology
64484 Clearance of actinic keratosis (AK) with tirbanibulin: Comparing results from controlled trials with real-world clinical studies
2025 · Neal Bhatia, George Martin, et al. · Journal of the American Academy of Dermatology
64609 Safety and tolerability of tirbanibulin for the treatment of actinic keratosis (AK): Results from clinical trials and post-registration
2025 · Andrew Blauvelt, Mark Lebwohl, et al. · Journal of the American Academy of Dermatology
53899 Treatment success with sarecycline for treatment of acne vulgaris (AV): Comparison of results from randomized controlled trials (RCTs) and the real-world (RW) PROSES study
2024 · Emmy Graber, James Del Rosso, et al. · Journal of the American Academy of Dermatology
54040 Efficacy of tirbanibulin for the treatment of actinic keratoses (AK): Comparison of results from randomized controlled trials (RCTs) and those from the real-world (RW) PROAK study
2024 · Todd Schlesinger, Ismail Kasujee, et al. · Journal of the American Academy of Dermatology
PDF
43102 Efficacy of Sarecycline for Facial Acne Vulgaris in Patients With Skin of Color: Post Hoc Analysis of Phase 3 Trials
2023 · Jonette Keri, Julie Harper, et al. · Journal of the American Academy of Dermatology
PDF
43185 Efficacy of Sarecycline for Truncal Acne in Patients With Skin of Color: Post Hoc Analysis of Phase 3 Trials
2023 · Julie Harper, Emmy Graber, et al. · Journal of the American Academy of Dermatology
PDF
43739 Safety and Tolerability of Tirbanibulin Ointment 1% over a Large Field (up to 100 cm2) in Actinic Keratosis: A Phase 3 Study
2023 · Neal Bhatia, Andrew Blauvelt, et al. · Journal of the American Academy of Dermatology
PDF
43735 Safety and Tolerability of a single 5-day Treatment Cycle of Tirbanibulin Ointment 1% in Large Field (100cm2): A phase I Trial in patients with Actinic Keratosis
2023 · Janet DuBois, Terry M. Jones, et al. · Journal of the American Academy of Dermatology
PDF
43140 Impact of Sarecycline on Quality of Life in Skin of Color Patients with Acne Vulgaris: Post Hoc Analysis of Phase 3 Trials
2023 · Andrew Alexis, Hilary Baldwin, et al. · Journal of the American Academy of Dermatology
PDF
Human Skin Absorption and Penetration Study of Four Different Topical Formulations of 5-Fluorouracil
2022 · Brian Berman, Paul Tomondy · SKIN The Journal of Cutaneous Medicine
PDF
Sustained effect of dupilumab with concomital topical corticosteroids on healrh-related quality of life in patients with moderate-to-severe atopic dermatitis: liberty ad chronos
2019 · Kim Papp, Pedro Herranz, et al.
Fluoroquinolone use for acute cystitis in an IPA-model managed care organization
1995 · John F. Aforismo, Alan F. Kaul, et al. · American Journal of Health-System Pharmacy
Works count: 23
Citation count: 19
H-index: 1
I10-index: 1
Year
Topic
Type